Shares of PaxMedica, Inc. (NASDAQ:PXMD – Get Free Report) traded down 4.6% during trading on Tuesday . The stock traded as low as $0.21 and last traded at $0.21. 16,999 shares were traded during mid-day trading, a decline of 99% from the average session volume of 1,320,100 shares. The stock had previously closed at $0.22.
PaxMedica Stock Down 4.6 %
The company’s 50 day moving average is $0.37 and its 200 day moving average is $0.53.
PaxMedica (NASDAQ:PXMD – Get Free Report) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.07). As a group, analysts forecast that PaxMedica, Inc. will post -1.09 earnings per share for the current fiscal year.
PaxMedica Company Profile
PaxMedica, Inc, a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome.
See Also
- Five stocks we like better than PaxMedica
- What is a Secondary Public Offering? What Investors Need to Know
- Chipotle Mexican Grill Stock Split: Where Does it Go From Here?
- Industrial Products Stocks Investing
- Arm Holdings and Micron: Top 2 AI Stocks to Buy and Hold
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Best Buy Stock May Be Best Bought Before the Holiday Season
Receive News & Ratings for PaxMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PaxMedica and related companies with MarketBeat.com's FREE daily email newsletter.
